Skip to content

The Impact of Baumann Skin Type Classification on Facial Surgical Wound Healing and Scar Formation

The Impact of Baumann Skin Type Classification on Facial Surgical Wound Healing and Scar Formation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600116855
Enrollment
Unknown
Registered
2026-01-15
Start date
2026-01-15
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Benign facial tumor

Interventions

Group of benign facial tumors observation:None

Sponsors

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Aged between 18 and 60 years; 2.Clinically and postoperatively pathologically confirmed to have a facial benign tumor (such as melanocytic nevus, sebaceous cyst, seborrheic keratosis, etc.) and having undergone standard surgical treatment. 3.Voluntarily participate in this study and sign a written informed consent form. 4.Commit to complying with all procedures set in this study and cooperate in completing all follow-ups and data collection work.

Exclusion criteria

Exclusion criteria: 1.Clinically or postoperatively pathologically confirmed to have a facial malignant tumor. 2.Requires staged excision or wounds planned for secondary healing. 3.The surgical site is located on or adjacent to the mucosal surface. 4.Known history of allergies to medications, dressings, etc., to be used during or after surgery. 5.Presence of systemic diseases that severely affect wound healing (such as poorly controlled diabetes, immunodeficiency diseases, active infections, etc.). 6.Currently using medications that affect wound healing or scar formation (such as long-term use of glucocorticoids, immunosuppressants, etc.). 7.Pregnant or lactating women. 8.Refusal to sign the informed consent form, or anticipated difficulty in cooperating with study follow-ups and data collection. 9.Concurrent participation in other interventional clinical trials. 10.Other factors judged by the investigator as potentially interfering with study results or increasing participant risk.

Design outcomes

Primary

MeasureTime frame
Stony Brook Scar Assessment Scale score;

Secondary

MeasureTime frame
Complications related to wound healing;Skin Disease Quality of Life Index;

Countries

China

Contacts

Public ContactLiu Yang

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

bengpao82@163.com+86 27 85768188

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026